Revolutionary Autoinjector Pushes the Limits of High Viscosity Drug Delivery
News Apr 18, 2013
Oval is a cutting-edge autoinjector company based in Cambridge UK. Their autoinjector technology solves currently unsolvable problems in the industry for drug containment and for the end user. Oval are highly focussed and agile, and it is therefore not surprising that they are proving to be a global success and are continuously growing their team.
The automatic delivery of high viscosity drugs is an important milestone for injection delivery, as there is currently no-known automatic injection device, with a needle, on the market which can deliver these viscosities. Viscosity has been a huge problem for many biopharmaceutical formulators as many biologics are very viscous. There has been no effective way of delivering high viscosity drugs through a prefilled syringe, without extreme pain to the patient (due a large needle bore) and physical discomfort, to the care-giver, when administering the injection (due to high injection forces). Not only does this mean that these wonder drugs (often coined magic bullets) can be administered through the Oval device, but they can be administered by the patient in the comfort of their own home.
Oval has wide experimental expertise in the design and testing of primary drug containers, for high viscosity drugs, in their specifically designed laboratories. Testing of pharmaceutical companies’ drugs, to see if they can be delivered in an Oval device, is proving to be a popular service for biopharmaceutical companies. Oval also has a new technology which should enable much higher viscosities (100,000 cPs) to be administered subcutaneously.
MIT chemical engineers have devised a new way to create very tiny droplets of one liquid suspended within another liquid, known as nanoemulsions. They also found a way to easily convert the liquid nanoemulsions to a gel when they reach body temperature, which could be useful for developing materials that can deliver medication when rubbed on the skin or injected into the body.
A team has developed a drug delivery system using curcumin, the main ingredient in the spice turmeric, that successfully inhibits bone cancer cells while promoting growth of healthy bone cells. The system inhibited the growth of cancer cells by 96% after 11 days as compared to untreated samples.READ MORE